Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753382 | 0.84 | MAPT (0.58) | L3MBTL1GABRA5MAPT | |
| SCHEMBL31747272 | 0.84 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL31752610 | 0.83 | NNMT (0.54) | L3MBTL1MAPTNNMT | |
| SCHEMBL15565594 | 0.81 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL23537880 | 0.81 | MAPK1 (0.56) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL31747492 | 0.81 | MAPK1 (0.49) | MAPK1KDM4EL3MBTL1MAPTMAOB | |
| SCHEMBL4843142 | 0.80 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL23538185 | 0.80 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL19590814 | 0.80 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1GABRA5MAPT | |
| SCHEMBL31747479 | 0.80 | MAPK1 (0.48) | MAPK1KDM4EL3MBTL1MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |